Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07569315
PHASE2

Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders

Sponsor: Bedaya Hospital

View on ClinicalTrials.gov

Summary

The aim of this randomized controlled study is to compare the efficacy of three successive doses of a GnRH agonist ( administered 36 , 24 and 12 hours before oocyte retrieval ) with a single dose of a GnRH agonist ( administered 36 hours before oocyte retrieval ) in triggering ovulation in hyper-responders

Official title: Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders Undergoing IVF Cycle. A Randomized Controlled Study.

Key Details

Gender

FEMALE

Age Range

18 Years - 40 Years

Study Type

INTERVENTIONAL

Enrollment

190

Start Date

2026-06-01

Completion Date

2028-04-01

Last Updated

2026-05-06

Healthy Volunteers

No

Conditions

Interventions

DRUG

Successive doses GnRH agonist

GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup. Two additional doses of triptorelin ( 0.1 mg / S.C ) are administered subcutaneously 12 and 24 hours after the first dose of GnRH agonist.

DRUG

Single dose GnRH agonist

GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup.

Locations (1)

Bedaya Hospital

Giza, Egypt